Compare Cigna Corp (CI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Mesoblast Limited — how do they compare? Cigna Corp trades at $302.09 (market cap $80.55B), while Mesoblast Limited trades at $16.95 (market cap $2.09B). The key difference: Cigna Corp is far larger — about 38.5× Mesoblast Limited's market cap, and Cigna Corp pays a 2.05% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| CI | MESO | |
|---|---|---|
Market Cap | $80.55B | $2.09B |
Sector | Health | Technology |
52-Week High | $311.00 | $20.96 |
52-Week Low | $244.41 | $10.96 |
Enterprise Value | $103.65B | $2.10B |
Dividend Yield | 2.05% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
